Clinical trials: Schizophrenia Therapeutics
Schizophrenia
Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.
- Trial name
- NCT00455663
- Testing
- Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia
The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
- Trial name
- NCT00077714
- Testing
- Paliperidone ER
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
An exploratory, double-arm, 4-week study to explore the feasibility and acceptability of abbreviated treatment with CT-156 for people with Schizophrenia.
- Trial name
- NCT06136936
- Testing
- CT-156-C-001
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
This is a Phase 3, open label study administering RBP-7000 in the treatment of patients with schizophrenia. Study will assess the long-term safety and tolerability of RBP-7000 subcutaneous (SC) injections in subjects with…
- Trial name
- NCT02203838
- Testing
- RBP-7000
- Where
- 48 sites in United States
- Volunteers
- 500 people
- Sponsor
- Indivior Inc.
Schizophrenia
Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders
The study examined the 12-month effectiveness of continuous therapeutic assertive community treatment (ACT) as part of integrated care (IC) compared to standard care (SC) in a catchment area comparison design in patients with…
- Trial name
- ACCESS (NCT01081418)
- Testing
- Assertive Community Treatment (ACT)
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Clinical High Risk for Psychosis (CHR), Psychotic Disorders
Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis
The goal of this study is to learn whether an accelerated form of neuromodulation therapy is safe, feasible, and well tolerated in young people at clinical high risk for psychosis (CHR-P), and whether it is associated with…
- Conditions
- Clinical High Risk for Psychosis (CHR), Psychotic Disorders, Prodromal Symptoms
- Trial name
- TMS-CHR (NCT07786714)
- Testing
- Active Intermittent Theta Burst Stimulation (BEAM-F3 Targeting)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Schizophrenia
Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia is a devastating and complex illness, with multiple symptom and behavioral manifestations. Antipsychotic medications are the mainstay of treatment; however, many patients only partially respond to treatment.
- Trial name
- NCT02118610
- Testing
- L-tetrahydropalmatine (30mg), Sugar pill
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Mental Disorders
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
The primary purpose of this study is to determine whether naltrexone is effective in the treatment of alcohol dependence and abuse in patients with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Mental Disorders, Alcohol Abuse, Alcoholism
- Trial name
- NCT00145847
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- State University of New York - Upstate Medical University
Schizophrenia
NRX-1074 in Early Course Schizophrenia
This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which have demonstrated inconsistent results for negative…
- Trial name
- NCT02603458
- Testing
- NRX-1074
- Where
- 2 sites in United States
- Sponsor
- NYU Langone Health
Care Burden, Schizophrenia
The Effect of Acceptance and Commitment Therapy Intervention on Caregiver Burden in Caregivers of Schizophrenia Patients
The aim of this study was to learn the effects of Acceptance and Commitment Therapy based stress management program on psychological flexibility and caregiver burden in caregivers of schizophrenia patients.
- Conditions
- Care Burden, Schizophrenia, Caregiver Mental Health
- Trial name
- NCT06799325
- Testing
- acceptance and commitment therapy based stress management program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Cumhuriyet University
Schizophrenia and Related Disorders
Clay Therapy in Schizophrenia Patients
In recent years, art therapies have been discussed for their positive effects on mental disorders. One such therapy, clay therapy, is being studied to examine its effect on the functional recovery and individual and social…
- Trial name
- NCT07378150
- Testing
- Clay therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 17 people
- Sponsor
- Kutahya Health Sciences University
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophrenia
Computer Assisted Cognitive Remediation Program in Schizophrenia
The purpose of this study is to determine whether computer-assisted cognitive remediation therapy is effective in the treatment of cognitive deficits in schizophrenia.
- Trial name
- CACREPS (NCT01598220)
- Testing
- Computer-assisted cognitive remediation therapy, attentional task
- Where
- Spain
- Volunteers
- 135 people
- Sponsor
- Gemma Garrido García
Schizophrenia, Schizoaffective
An Open Trial of Cysteamine Treatment in Schizophrenia
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
- Trial name
- NCT01139125
- Testing
- (Cystagon) Cysteamine Bitartrate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Augusta University
Schizophrenia
Safety and Tolerability of Risperidone Implants
A one year, open-label, study to evaluate the safety and tolerability of risperidone implants as a maintenance treatment in patients with schizophrenia
- Trial name
- NCT02773576
- Testing
- Risperidone implant
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Psychosis
Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
- Trial name
- NCT00237874
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Systematic Evaluation of Antiviral Medication in Schizophrenia
The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes…
- Trial name
- SEAMS (NCT00514449)
- Testing
- Valacyclovir
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Konasale Prasad
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.